chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Chills; Fever; Nausea; Headache; General body pain / Body aches; Extreme tiredness; This is a spontaneous report received from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 24Mar2021 at 11:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient had no past medical history, however, the patient had allergies to penicillin, sulfonamide, codeine and clindamycin. The concomitant medications include red yeast rice (MANUFACTURER UNKNOWN), zyrtec (MANUFACTURER UNKNOWN), CoQ10 (MANUFACTURER UNKNOWN), magnesium (MANUFACTURER UNKNOWN), vitamin E (MANUFACTURER UNKNOWN) and vitamin D (MANUFACTURER UNKNOWN) all for an unspecified indication from an unspecified date. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Mar2021 at 12:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not tested for COVID-19. On 25Mar2021 at 04:30, the patient experienced chills, fever, nausea, headache, general body pain (body aches) and extreme tiredness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No treatment was received for the reported events. The clinical outcome of the events chills, fever, nausea, headache, general body pain (body aches), extreme tiredness was recovered on an unspecified date.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Defaecation urgency, Diarrhoea, Flushing
Clinical narrative: Flushing on chest; loose stool; urgency to go tobathroom for two days; This is a spontaneous report from a contactable other healthcare professional, the patient. A 56-years-old, non-pregnant female received first dose of BNT162b2 (PFIZER BIONTECH mRNA COVID-19 vaccine; Lot number: UNKNOWN) via an unspecified route of administration in right arm on 23Mar2021 at 13:30 (at the age of 56-years-old) for COVID-19 immunisation. The patient medical history includes supraventricular tachycardia. Concomitant medications include atenolol (MANUFACTURER UNKNOWN) taken within two weeks of vaccination. The patient has known allergy to aspirin(MANUFACTURER UNKNOWN). Prior to vaccination, patient has not been diagnosed with COVID-19. Since the vaccination, patient has not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Mar2021 at 14:30, the patient experienced flushed chest and loose stools with urgency to go the bathroom for two days. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care The clinical outcome of events flushed chest, loose stools and increased stool urgency was unknown at the time of this report. No follow-up attempts are possible; information about lot number cannot be obtained.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Headache, Muscle fatigue
Clinical narrative: Headache; muscle fatigue; dizziness; This is a spontaneous report from non-contactable patient. A 37-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA; Lot Number: UNKNOWN), via an unspecified route of administration on an unknown date (at the age of 37-year-old) as single dose for COVID-19 immunisation. Medical history was not reported. The patient was allergic to sulfa drugs. Concomitant medications were not reported. The patient was not diagnosed with COVID-19 prior to the vaccination and since the vaccination, the patient has not tested positive for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 24Mar2021 the patient experienced headache, muscle fatigue and dizziness. The patient did not receive any treatment for the events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events such as headache, muscle fatigue and dizziness were recovered on an unknown date at the time of reporting.   Information about lot number cannot be obtained. No further information is expected.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: My lymph nodes are swollen pretty bad; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202) via an unspecified route of administration in the right arm on 03Mar2021 at 12:00 (at the age of 52-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an unspecified route of administration in right arm on 24Mar2021 (at the age of 52-years-old) as single for COVID-19 immunisation. Medical history included asthma and hernia. The patient had a history of allergy to penicillin (MANUFACTURER UNKNOWN) and ibuprofen (MANUFACTURER UNKNOWN). The concomitant medications included omeprazole (MANUFACTURER UNKNOWN) and ciprofloxacin (MANUFACTURER UNKNOWN) for an unknown indication. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient experienced swollen lymph nodes on 17Mar2021 at 13:15. Therapeutic measure was taken as a result of swollen lymph nodes and included treatment with antibiotics. The adverse events resulted in doctor or other health care professional or clinic visit. The clinical outcome of swollen lymph nodes was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Throat tightness
Clinical narrative: both doses, throat tightness; This is a spontaneous report from a contactable physician. A 63-years-old female patient received bnt162b2 (BNT162B2) via an unspecified route of administration on an unspecified date (Batch/Lot Number: FN6205) as DOSE 1, SINGLE for covid-19 immunisation. Medical history included asthma, environmental allergy, chronic myeloid leukemia and overactive bladder. Past drug history included fluticasone propionate, salmeterol xinafoate (ADVAIR) 100/50 twice daily inhalation taken for asthma from an unspecified start date and ongoing, azelastine hydrochloride, fluticasone propionate (DYMISTA) 1 spray each nostril twice daily taken for environmental allergy from an unspecified start date and ongoing; dasatinib monohydrate (SPRYCEL, NDC: 0003-0524-11) 70 mg, one tablet every evening taken for chronic myeloid leukaemia from 2013 to an unspecified stop date; spironolactone (SPIRONOLACTONE) 25 mg once daily taken for fluid retention from 2017 to an unspecified stop date and mirabegron (MYRBETRIQ) 50 mg once daily by mouth taken for hypertonic bladder, start and stop date were not reported. On an unspecified date, the patient experienced some throat tightness the day of the COVID vaccine that dissipated late that afternoon and that was for both doses. Caller was calling about the Pfizer BioNtech COVID vaccine. She had some throat tightness the day of the COVID vaccine that dissipated late that afternoon and that was for both doses. The outcome of the event both doses, throat tightness was recovered on an unspecified date.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Pain in extremity
Clinical narrative: chills; Headache; fatigue; Sorearm; This is a spontaneous report from a non-contactable consumer, the patient. A 60-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: En6203) via an unspecified route of administration in the left arm on 18Mar2021 at 14:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included sulphonamide allergy and bee sting allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 25Feb2021 at 14:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other medication within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, patient had not been tested for COVID-19. On 18Mar2021, the patient experienced chills, headache, fatigue and sore arm. No therapeutic measures were taken as a result of the event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events chills, headache, fatigue and sore arm was recovered on an unknown date.   No follow-up attempts are needed. No further information is expected.
Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: slight fever; This is a spontaneous report from a contactable nurse. A 16-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration on an unknown date( at the age of 16-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On unspecified date in Mar2021, the patient experienced slight fever. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of slight fever was recovered on unspecified date in Mar2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Decreased appetite, Pain, Pyrexia, Viral test
Clinical narrative: Fevers for 3 full days following seconddose; Body aches; Loss of appetite; This is a spontaneous report from a contactable pharmacist, the patient. A 29-year-old female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via unspecified route of administration in right arm, on 29Jan2021 at 16:45 (at the age of 29 years) as a single dose for COVID-19 immunisation. Medical history included seasonal allergies. Concomitant medications were not provided. The patient received other medications (unspecified) within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via unspecified route of administration in left arm on 08Jan2021 at 16:45 (at the age of 29 years) as a single dose for COVID-19 Immunisation. On 29Jan2021 at 23:00 hours the patient experienced fevers for 3 full days following second dose, body aches and loss of appetite. The adverse events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient underwent lab tests and procedures, which included nasal swab COVID-19 virus test on 10Mar2021 and tested negative. No therapeutic measures were taken for the events. The clinical outcome for the events fever, body aches and loss of appetite was recovered on unknown date in 2021.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Pain in extremity
Clinical narrative: Headache; sore arm; Tired, minor; This is a spontaneous report from a non-contactable consumer, the patient. A 33-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3247) via an unspecified route of administration on an unspecified date (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. On an unknown date, the patient experienced headache, tired, minor, and sore arm. The clinical outcomes of the events headache, tired, minor, and sore arm were unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Feeling abnormal, Myalgia, Pain
Clinical narrative: Chills; fatigue; muscle aches; body ache; did not feel like myself after this first injection; This is a spontaneous report from a non-contactable consumer, the patient. A 67-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL8982), via an unspecified route of administration on 15Mar2021 at 08:30 (at the age 67-years-old), as a single dose for COVID-19 immunisation. Medical history included atrial fibrillation. The patient had no allergies to medications, food, or other products. Concomitant medications included diltiazem (CARDIZEM) and apixaban (ELIQUIS); both for unspecified indication from unknown date. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 15Mar2021, about 4 to 6 hours after the vaccination, the patient experienced chills, fatigue, muscle aches, body aches. The patient did not feel like himself. The patient had been known to have a very good immune system. The second dose was due on 05Apr2021 (as reported). The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of chills, fatigue, muscle aches, body aches and feeling abnormal was recovered on an unspecified date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Headache, Nausea, Pain
Clinical narrative: Achy; Pain in arm; Fever; Chills; Headache; nausea; Lightheaded; This is a spontaneous report from a contactable consumer. A 51-year-old non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN)  via an unspecified route of administration in the right arm on 24Mar2021 at 12:15 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. The patient medical history included many (unspecified details).The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the right arm on 03Mar2021 at 12:15 PM(at the age of 51-years-old)  as a single dose for COVID-19 immunisation.  The patient had allergies to medications, food, or other products. The patient received unspecified medication within 2 weeks of COVID-19 vaccine. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19.On 25Mar2021 the patient at 01:30, experienced achy, pain in arm, fever, chills, headache, lightheaded and nausea. The patient did not receive any treatment for the events. The clinical outcome of  achy, pain in arm, fever, chills, headache, lightheaded and nausea was recovering at the time of this report. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care visit. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Pyrexia
Clinical narrative: Achy; Pain in arm; Fever; Chills; Headache; nausea; Lightheaded; This is a spontaneous report from a contactable consumer. A 51-year-old non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN)  via an unspecified route of administration in the right arm on 24Mar2021 at 12:15 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. The patient medical history included many (unspecified details).The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the right arm on 03Mar2021 at 12:15 PM(at the age of 51-years-old)  as a single dose for COVID-19 immunisation.  The patient had allergies to medications, food, or other products. The patient received unspecified medication within 2 weeks of COVID-19 vaccine. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19.On 25Mar2021 the patient at 01:30, experienced achy, pain in arm, fever, chills, headache, lightheaded and nausea. The patient did not receive any treatment for the events. The clinical outcome of  achy, pain in arm, fever, chills, headache, lightheaded and nausea was recovering at the time of this report. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care visit. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Dysphagia, Lip swelling, Peripheral swelling, SARS-CoV-2 test
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202) via an unspecified route of administration in the right arm on 13Mar2021 at 13:15 (at the age of 41-years) as a single dose for COVID-19 immunisation. Medical history included pancreatitis, high blood pressure and dizziness. Concomitant medications included prednisone (MANUFACTURER UNKNOWN) 1 dose the day after and losartan (MANUFACTURER UNKNOWN) for unknown indication. The patient previously received tobramycin (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 15Mar2021 at 18:00, the patient experienced face, neck, lips, and hands swollen, trouble swallowing and increased dizziness. The adverse events resulted in emergency room or urgent care visit. On 22Mar2021, post vaccination, the patient had nasal swab test and was tested negative. The patient did not receive any treatment for the adverse events swollen face, swollen neck, swollen lips, swollen hands, trouble swallowing and increased dizziness. The clinical outcomes of the events swollen face, swollen neck, swollen lips, swollen hands, trouble swallowing and increased dizziness were recovered on an unknown date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling, Swelling face
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202) via an unspecified route of administration in the right arm on 13Mar2021 at 13:15 (at the age of 41-years) as a single dose for COVID-19 immunisation. Medical history included pancreatitis, high blood pressure and dizziness. Concomitant medications included prednisone (MANUFACTURER UNKNOWN) 1 dose the day after and losartan (MANUFACTURER UNKNOWN) for unknown indication. The patient previously received tobramycin (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 15Mar2021 at 18:00, the patient experienced face, neck, lips, and hands swollen, trouble swallowing and increased dizziness. The adverse events resulted in emergency room or urgent care visit. On 22Mar2021, post vaccination, the patient had nasal swab test and was tested negative. The patient did not receive any treatment for the adverse events swollen face, swollen neck, swollen lips, swollen hands, trouble swallowing and increased dizziness. The clinical outcomes of the events swollen face, swollen neck, swollen lips, swollen hands, trouble swallowing and increased dizziness were recovered on an unknown date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: hives on bilateral arms/legs, trunk, hands, feet, and neck; This is a spontaneous report from a contactable other healthcare professional, the patient. A 31-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: unknown) via unspecified route of administration in the left arm on 19Mar2021 at 18:45 (at the age of 31-years-old), as a single dose for COVID-19 immunisation. The patient medical history included polycystic ovarian syndrome from unknown date. The patient had allergy to sulfa drugs and wasps. The patient did not take any concomitant medication. The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 00:00, the patient experienced hives on bilateral arms/legs, trunk, hands, feet and neck. The patient did not receive any treatment for the reported event. The event resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event urticaria was not recovered at the time of reporting.    Information about lot/batch number cannot be obtained. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Asthma, Dust allergy, Lymphadenopathy, Rash erythematous
Clinical narrative: 48 hours after vaccination, developed swollen lymph nodes on right neck (front and back); Red rash spots on neck; 8 hours after, started to feel asthma; Felt like when exposed to a lot of dust and very allergic to dust mites; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received first dose of BNT162b2 (COVID-19 MRNA VACCINE BIONTECH; Lot number: ER8730) via unspecified route of administration in left arm on 22Mar2021 at 08:00 as a single dose (at the age of 56-years-old) for COVID-19 immunisation. The patient had known allergies to sulfonamides and monosodium glutamate. The patients medical history included hypertension and asthma. The concomitant medications included valsartan (MANUFACTURER UNKNOWN) 180 mg used once daily for an unknown indication and multivitamin for women (MANUFACTURER UNKNOWN) for an unknown indication. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 22Mar2021 at 15:00, 8 hours after the vaccine shot, the patient felt the asthma as she has allergic asthma and felt like when she was exposed to a lot of dust as she was very allergic to dust mites; On 24Mar2021 at 08:00, 48 hours after the shot, the patient experienced swollen lymph nodes on right neck (front and back) and red rash spots on the neck. No treatment was received for the events. The clinical outcome of the reported events was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Taste disorder
Clinical narrative: Loss of taste of anything sweet; This is a spontaneous report from a contactable consumer, the patient. A 50-years-old non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6208), via unspecified route of administration in the left arm at 15:45 on 27Mar2021 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. Patient was allergic to penicillin. The concomitant medications included iron (MANUFACTURER UNKNOWN) and b12 (MANUFACTURER UNKNOWN). The patient previously received first dose BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: EN6198) at 15:00 left arm on 06Mar2021 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 27Mar2021 at 20:00, patient felt loss of taste of anything sweet. The adverse events did not result in doctor or other healthcare professional office/clinic visit. The patient did not receive treatment for the reported events. The clinical outcome of the event loss of taste of anything sweet was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Epistaxis
Clinical narrative: Nose bleed right nostril; This is a spontaneous report received from a contactable consumer, the patient. A 60-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8730) via an unspecified route administration in the left arm on 28Mar2021 at 16:00 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. The patient had as medical history of atrial fibrillation and allergies with penicillin, bee stings and mosquito bites. The patient received diltiazem (MANUFACTURER UNKNOWN) 120mg for day, melatonin (MANUFACTURER UNKNOWN) 10mg for day and cetirizine hydrochloride (ZYRTEC) within 2 weeks of vaccination. The patient had received erythromycin (MANUFACTURER UNKNOWN), tetracycline and cipro (MANUFACTURER UNKNOWN) in the past and experienced drug allergy. The patient had not received other vaccines within 4 weeks prior to vaccination. Prior to vaccination, the patient had not been diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 29Mar2021 at 15:45, the patient experienced with nose bleed right nostril, it was mild flow that she was able to stop by pinching her nose and she has not had a true nose bleed before. The adverse events did not result in doctor or other healthcare professional office/clinic visit. The patient did not receive treatment for the reported event. The clinical outcome of the event was recovered at the time of report.   No follow-up attempts are needed. No further information is expected
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Blood bilirubin, Blood bilirubin increased, Blood glucose, Blood glucose increased, Blood pressure increased
Clinical narrative: Significant fatigue; Extremely Lethargic; Erratic heart rate; No appetite; Chills; Glucose and bilirubin slightly elevated; Glucose and bilirubin slightly elevated; Extremely rapid heart rate; Elevated blood pressure; Dry mouth; Lightheaded; Shakes; This is a spontaneous report from a contactable consumer (patient). A 49-year-old male patient received first dose of BNT162B2 via an unspecified route of administration at arm left on 25Mar2021 13:15 (age at 49 years old, Batch/Lot Number: EP6955) as single dose for COVID-19 immunisation. Medical history reported as none. The patient was not diagnosed with COVID-19 prior to vaccination and the patient did not test for COVID-19 since the vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications included cetirizine hydrochloride (ZYRTEC); vitamins nos (MULTIVITAMIN); fish oil; all as supplement. About 5 mins after injection (25Mar2021 13:30), the patient developed extremely rapid heart rate and elevated blood pressure, dry mouth, lightheaded and shakes. The patient went to emergency room (ER), heart rate stabilized after about 60 mins. Blood work and EKG were normal on 25Mar2021. Next day on 26Mar2021, the patient developed extremely lethargic, erratic heart rate, no appetite. The following evening, the patient had another the same episode as post injection, rapid heart rate, chills, elevated blood pressure. The patient went to ER, EKG/Chest x-ray/blood tests all normal (glucose and bilirubin slightly elevated) on 26Mar2021. 4 days post injection (29Mar2021), heart rate still erratic and significant fatigue, heart rate spiked with little effort. The events required Doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. The patient received iv fluids as treatment. All events were not recovered.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Blood pressure measurement, Blood test, Chest X-ray, Chills, Decreased appetite
Clinical narrative: Significant fatigue; Extremely Lethargic; Erratic heart rate; No appetite; Chills; Glucose and bilirubin slightly elevated; Glucose and bilirubin slightly elevated; Extremely rapid heart rate; Elevated blood pressure; Dry mouth; Lightheaded; Shakes; This is a spontaneous report from a contactable consumer (patient). A 49-year-old male patient received first dose of BNT162B2 via an unspecified route of administration at arm left on 25Mar2021 13:15 (age at 49 years old, Batch/Lot Number: EP6955) as single dose for COVID-19 immunisation. Medical history reported as none. The patient was not diagnosed with COVID-19 prior to vaccination and the patient did not test for COVID-19 since the vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications included cetirizine hydrochloride (ZYRTEC); vitamins nos (MULTIVITAMIN); fish oil; all as supplement. About 5 mins after injection (25Mar2021 13:30), the patient developed extremely rapid heart rate and elevated blood pressure, dry mouth, lightheaded and shakes. The patient went to emergency room (ER), heart rate stabilized after about 60 mins. Blood work and EKG were normal on 25Mar2021. Next day on 26Mar2021, the patient developed extremely lethargic, erratic heart rate, no appetite. The following evening, the patient had another the same episode as post injection, rapid heart rate, chills, elevated blood pressure. The patient went to ER, EKG/Chest x-ray/blood tests all normal (glucose and bilirubin slightly elevated) on 26Mar2021. 4 days post injection (29Mar2021), heart rate still erratic and significant fatigue, heart rate spiked with little effort. The events required Doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. The patient received iv fluids as treatment. All events were not recovered.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Dry mouth, Electrocardiogram, Fatigue, Heart rate
Clinical narrative: Significant fatigue; Extremely Lethargic; Erratic heart rate; No appetite; Chills; Glucose and bilirubin slightly elevated; Glucose and bilirubin slightly elevated; Extremely rapid heart rate; Elevated blood pressure; Dry mouth; Lightheaded; Shakes; This is a spontaneous report from a contactable consumer (patient). A 49-year-old male patient received first dose of BNT162B2 via an unspecified route of administration at arm left on 25Mar2021 13:15 (age at 49 years old, Batch/Lot Number: EP6955) as single dose for COVID-19 immunisation. Medical history reported as none. The patient was not diagnosed with COVID-19 prior to vaccination and the patient did not test for COVID-19 since the vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications included cetirizine hydrochloride (ZYRTEC); vitamins nos (MULTIVITAMIN); fish oil; all as supplement. About 5 mins after injection (25Mar2021 13:30), the patient developed extremely rapid heart rate and elevated blood pressure, dry mouth, lightheaded and shakes. The patient went to emergency room (ER), heart rate stabilized after about 60 mins. Blood work and EKG were normal on 25Mar2021. Next day on 26Mar2021, the patient developed extremely lethargic, erratic heart rate, no appetite. The following evening, the patient had another the same episode as post injection, rapid heart rate, chills, elevated blood pressure. The patient went to ER, EKG/Chest x-ray/blood tests all normal (glucose and bilirubin slightly elevated) on 26Mar2021. 4 days post injection (29Mar2021), heart rate still erratic and significant fatigue, heart rate spiked with little effort. The events required Doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. The patient received iv fluids as treatment. All events were not recovered.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Heart rate increased, Heart rate irregular, Lethargy, Tremor
Clinical narrative: Significant fatigue; Extremely Lethargic; Erratic heart rate; No appetite; Chills; Glucose and bilirubin slightly elevated; Glucose and bilirubin slightly elevated; Extremely rapid heart rate; Elevated blood pressure; Dry mouth; Lightheaded; Shakes; This is a spontaneous report from a contactable consumer (patient). A 49-year-old male patient received first dose of BNT162B2 via an unspecified route of administration at arm left on 25Mar2021 13:15 (age at 49 years old, Batch/Lot Number: EP6955) as single dose for COVID-19 immunisation. Medical history reported as none. The patient was not diagnosed with COVID-19 prior to vaccination and the patient did not test for COVID-19 since the vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications included cetirizine hydrochloride (ZYRTEC); vitamins nos (MULTIVITAMIN); fish oil; all as supplement. About 5 mins after injection (25Mar2021 13:30), the patient developed extremely rapid heart rate and elevated blood pressure, dry mouth, lightheaded and shakes. The patient went to emergency room (ER), heart rate stabilized after about 60 mins. Blood work and EKG were normal on 25Mar2021. Next day on 26Mar2021, the patient developed extremely lethargic, erratic heart rate, no appetite. The following evening, the patient had another the same episode as post injection, rapid heart rate, chills, elevated blood pressure. The patient went to ER, EKG/Chest x-ray/blood tests all normal (glucose and bilirubin slightly elevated) on 26Mar2021. 4 days post injection (29Mar2021), heart rate still erratic and significant fatigue, heart rate spiked with little effort. The events required Doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. The patient received iv fluids as treatment. All events were not recovered.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Lymphadenopathy, Pain
Clinical narrative: a large swollen gland in right armpit; tired; achey; This is a spontaneous report from a non-contactable consumer, the patient. A 30-years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER 8733) via an unspecified route of administration on 27Mar2021 at 18:00 (at the age of 30-years-old) in right arm as a single dose for COVID-19 immunisation. The patient medical history included celiac, hashimotos diseases and allergies to food (gluten, mushrooms). Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), glucosamine (MANUFACTURER UNKNOWN), Lysine hydrochloride (LYSINE) and Levocetirizine dihydrochloride (XYZAL) all for unknown indications from unknown date. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205) via an unspecified route in left arm on 06Mar2021 at 18:15 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination the patient was not tested for COVID-19. On 28Mar2021, 24 hours after the vaccine the patient experienced achey and tired but this resolved after 6 hours. On 29Mar2021 at 19:00 the patient had noticed 48 hours after the vaccine a large swollen gland in right armpit. It was soft and tender to the touch. The adverse event did not resulted in a visit to emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events of achey and tired was recovered on 28Mar2021. The clinical outcome of the events of a large swollen gland in right armpit was not recovered at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pruritus, Vaccination site swelling
Clinical narrative: Swollen injection site and 3 other places within about 4 inches area below the injection site; Raised places itch; This is a spontaneous report from a non-contactable consumer, the patient. A 52-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Pfizer ER6207), via an unspecified route of administration in the right arm on 23Mar2021 at 09:00 (at the age of 52-years-old), as a single dose for COVID-19 immunisation. Medical history was reported as no. The patient had no known allergies to medications, food or other products. Concomitant medications included simvastatin (MANUFACTURER UNKNOWN), citalopram (MANUFACTURER UNKNOWN), and ergocalciferol (VITAMIN D); all from unknown dates for unspecified indications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6203), via an unspecified route of administration in the right arm on 19Feb2021 at 17:15 (at the age of 51-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 24Mar2021, the patient developed swollen injection site and three other places within about 4 inches area below the injection site. The raised places were itchy and had the same appearance as a mosquito bite. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events vaccination site swelling and vaccination site pruritus was recovering at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation irregular
Clinical narrative: Breakthrough menstrual bleeding 9 days before expected period start date, darker in color than usual.; This is a spontaneous report from a contactable healthcare professional, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6199), via an unspecified route of administration in the left arm on 25Mar2021 at 13:45 (at the age of 40-years-old), as a single dose for COVID-19 immunisation. Medical history included hashimoto's thyroiditis. The patient was not allergic to medications, food, or other products. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), liothyronine (MANUFACTURER UNKNOWN) and spironolactone (MANUFACTURER UNKNOWN). The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En5318), via an unspecified route of administration in the left arm on 04Mar2021 at 12:00 (at the age of 40-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks, prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 29Mar2021 at 10:00, the patient experienced breakthrough menstrual bleeding 9 days before expected period start date (irregular periods) and it was darker in colour than usual. The patient's last period start date was 08Mar2021 which was as expected. The patient did not receive any treatment for the reported event. The event did not result in doctor or other healthcare professional office/clinic visit. It was unknown if patient did receive any treatment for event. The clinical outcome of the event irregular periods was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Headache, Pyrexia
Clinical narrative: broke out in a 103.5 fever the next day.; I have had a very bad headache all day long; This is a spontaneous report from a non-contactable consumer, the patient. A 22-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) in the right arm on 18Mar2021 at 12:30 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) on an unknown date as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines in four weeks prior to COVID-19 vaccination. Prior to vaccination the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 19Mar2021, the patient broke out in a 103.5 (units unspecified) (body temperature) fever and also had a very bad headache all day long. The adverse events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of fever and headache (unspecified). The clinical outcome of the events fever and headache was unknown at the time of this report.   No follow-up attempts are possible; information about lot/ batch number cannot be obtained.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Allergy test, Body temperature, Chills, Confusional state, Fatigue
Clinical narrative: brain foggy; exhausted; weird arm pain in left arm.; on and off headache; Chills; shakes; fever; bruise where the vaccine was given; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 26Mar2021 at 11:00 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety, post-traumatic stress disorder, pollen allergy, house dust allergy, high cholesterol and blood pressure high when anxious. The patient had no allergies to medications, food, or other products and even the patient had a test at the allergist's prior to getting the vaccine to make sure that she wouldn't be allergic to any of the additives. Concomitant medications included buspirone hydrochloride (BUSPAR), hydrochlorothiazide (MANUFACTURER UNKNOWN) and Vit + Supplements (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021, the patient experienced bruise and on same day at 23:00, the patient experienced shakes, fever and chills. On 27Mar2021 (Saturday), the patient experienced on and off headache. On 27Mar2021, the patient underwent test for body temperature and the result was 101.5 degrees Fahrenheit. The patient took Advil and drank plenty of fluids due to headache and fever. On 28Mar2021 (Sunday), the patient was exhausted and experienced weird arm pain in left arm. On 28Mar2021, the patient underwent test for body temperature and the result was 100.4 degrees Fahrenheit and she continued with the Advil and fluids. On29Mar2021 (Monday), the patient had foggy brain (confusion). The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the events bruise, chills, shaking, fever, headache, exhaustion, brain foggy and pain in arm was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pain in extremity, Pyrexia, Tremor, Vaccination site bruising
Clinical narrative: brain foggy; exhausted; weird arm pain in left arm.; on and off headache; Chills; shakes; fever; bruise where the vaccine was given; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 26Mar2021 at 11:00 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety, post-traumatic stress disorder, pollen allergy, house dust allergy, high cholesterol and blood pressure high when anxious. The patient had no allergies to medications, food, or other products and even the patient had a test at the allergist's prior to getting the vaccine to make sure that she wouldn't be allergic to any of the additives. Concomitant medications included buspirone hydrochloride (BUSPAR), hydrochlorothiazide (MANUFACTURER UNKNOWN) and Vit + Supplements (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021, the patient experienced bruise and on same day at 23:00, the patient experienced shakes, fever and chills. On 27Mar2021 (Saturday), the patient experienced on and off headache. On 27Mar2021, the patient underwent test for body temperature and the result was 101.5 degrees Fahrenheit. The patient took Advil and drank plenty of fluids due to headache and fever. On 28Mar2021 (Sunday), the patient was exhausted and experienced weird arm pain in left arm. On 28Mar2021, the patient underwent test for body temperature and the result was 100.4 degrees Fahrenheit and she continued with the Advil and fluids. On29Mar2021 (Monday), the patient had foggy brain (confusion). The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the events bruise, chills, shaking, fever, headache, exhaustion, brain foggy and pain in arm was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.